🇺🇸 FDA
Patent

US 11833221

Oligomeric compounds for reducing DMPK expression

granted A61KA61K47/549A61K47/6807

Quick answer

US patent 11833221 (Oligomeric compounds for reducing DMPK expression) held by Ionis Pharmaceuticals, Inc. expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Dec 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K47/549, A61K47/6807, A61K47/6849